Innovent Biologics

166 articles with Innovent Biologics

• Innovent Announces 2022 Annual Results and Business Updates

  3/28/2023

  Innovent Biologics, Inc. (Innovent) (HKEX: 01801) announces its 2022 annual results and major company business updates.

• Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023

  3/20/2023

  Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) today announced that clinical data from multiple trials in relation to TYVYT® (sintilimab injection), Pemazyre® (pemigatinib) and IBI351 (KRASG12C inhibitor) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, April 14 - 19, 2023.

• Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration

  2/27/2023

  Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the first participant with neovascular age-related macular degeneration (nAMD) has been successfully dosed in the phase 1 clinical trial of IBI333, a recombinant anti-VEGF–A and anti-VEGF-C bispecific fusion protein.

• Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

  2/16/2023

  Innovent Biologics, Group. announced that the first patient with moderate-to-severe plaque psoriasis has been successfully dosed in a Phase 3 clinical trial of picankibart, a recombinant anti-interleukin 23p19 subunit antibody injection.

• Innovent Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy

  2/15/2023

  Innovent Biologics, Inc. announces that the first patient with thyroid associated ophthalmopathy has been successfully dosed in the Phase 2 study of IBI311, a recombinant anti-insulin-like growth factor-1 receptor monoclonal antibody.

• China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

  1/19/2023

  Ascentage Pharma and Innovent Biologics, Inc., announced that the novel drug olverembatinib has been included into the China 2022 National Reimbursement Drug List（NRDL), for the treatment of T315I-mutant chronic-phase chronic myeloid leukemia and accelerated-phase CML.

• Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

  1/18/2023

  Innovent Biologics, Inc. today announced that, five products (including new indications) of the company have been included in the updated National Reimbursement Drug List (2022 Version) ("NRDL").

• Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

  1/10/2023

   Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the first participant has been successfully dosed in a multicenter, randomized, dulaglutide-controlled phase 3 clinical trial (DREAMS-2) of mazdutide (Innovent R&D Code: IBI362), a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese patients with type 2 diabetes.

• Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

  1/9/2023

  Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the first participant has been successfully dosed in a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial (DREAMS-1) of mazdutide (Innovent R&D Code: IBI362), a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese patients with type 2 diabetes.

• Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the NDA for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma

  1/6/2023

  Innovent Biologics, Inc. announces that the New Drug Application for parsaclisib for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two previous systemic therapies has been accepted for review by China's Center for Drug Evaluation of the National Medical Products Administration and granted Priority Review designation.

• Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer

  1/5/2023

  Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation for IBI351 for the treatment of advanced non-small cell lung cancer patients with KRASG12C mutation that have received at least one prior line of systemic therapy.

• Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Innovent Biologics, Inc. announced that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference held on January 9-12, 2023 in San Francisco and Dr. De-Chao Michael Yu, Founder, Chairman and CEO of Innovent will present on Wednesday, January 11, 2023 at 10:00am Pacific Standard Time.

• Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease

  12/15/2022

  Innovent Biologics and LG Chem Life Sciences announced that the two parties have entered into a strategic collaboration and license agreement regarding LG Chem's Tigulixostat, a late-stage novel non-purine xanthine oxidase inhibitor for the chronic management of hyperuricemia in patients with gout disease.

• Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting

  12/11/2022

  Innovent Biologics, Inc. announced that clinical data of IBI188 as first-line treatment in newly diagnosed higher risk myelodysplastic syndrome is presented at the 2022 American Society of Hematology Annual Meeting, held Dec 10-13, 2022.

• Innovent Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress

  12/9/2022

  Innovent Biologics, Inc. announced that updated clinical data of IBI110 in advanced squamous non-small cell lung cancer is presented at the 2022 European Society for Medical Oncology Immuno-Oncology Congress, held Dec 7-9, 2022.

• Innovent Presents Phase Ib Clinical Data of IBI939 (Anti-TIGIT Monoclonal Antibody) in Previously Untreated PD-L1-selected NSCLC at the 2022 European Society For Medical Oncology Immuno-Oncology Congress

  12/9/2022

  Innovent Biologics, Inc. announced that clinical data of IBI939 is presented at the 2022 European Society for Medical Oncology Immuno-Oncology Congress, Dec 7-9, 2022.

• Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)

  12/5/2022

  Innovent Biologics, Inc. and UNION therapeutics A/S announced that the first Chinese healthy volunteer has been successfully dosed in the Phase I study of orismilast, a potential best-in-class PDE4 inhibitor in global clinical Phase II stage.

• Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

  11/28/2022

  Innovent Biologics, Inc. announced that clinical data from multiple trials in relation to TYVYT®, olverembatinib, IBI188, IBI110 and IBI939 will be presented at the upcoming international medical conferences.

• Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting

  11/14/2022

  Innovent Biologics, Inc. presented the updated results of IBI351 from a phase Ia clinical trial at the 2022 Chinese Society of Clinical Oncology Annual Meeting.

• Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity

  11/14/2022

  Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the first participant has been successfully dosed in a phase 3 clinical trial (GLORY-1) of mazdutide (Innovent R&D Code: IBI362), a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with overweight or obesity.